

**RENEW Phase 3, multi-center, double-blind, randomized
MDS low-intermediate IPSS R with transfusion dependent anemia**

Contatti: P.I. Elena Crisà elena.crisa@ircc.it

Linea terapeutica: Refractory or intolerant to prior ESA treatment

Coorti: Sperimental Arm **Terapia:** Elritercept (KER-050)

Coorti: Control Arm **Terapia:** Placebo

Inclusion:

- Refractory or intolerant to prior ESA treatment (discontinued ≥ 8 weeks before randomization), or unlikely to respond to ESA treatment
- Less than 5% blasts in an evaluable bone marrow aspirate collected at Screening, read by an independent central reader

Exclusion:

- Del(5q) MDS or secondary MDS.
- Anemia due to any other known cause (e.g., thalassemia, hemolytic anemia, bleeding events, or deficiency of iron, B12, and/or folate).
- Receipt of RBC transfusion for any reason(s) other than underlying MDS within 16 weeks before randomization.
- Prior lifetime use of TGF- β -modulating therapy, including luspatercept